CI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cigna Group (CI) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive analyst ratings and a favorable long-term outlook, the recent financial performance, technical indicators, and cautious sentiment from Congress trading data suggest that this is not an optimal entry point. A hold strategy is recommended until clearer positive signals emerge.
The technical indicators are mixed to bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 59.081, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading close to its pivot level of 286.922, with resistance at 294.596 and support at 279.247.
Analysts have raised price targets significantly, with multiple firms maintaining Buy ratings. The company's Q4 results and 2026 guidance have been viewed positively, removing key overhangs like PBM reform and stop-loss issues. Additionally, the healthcare insurance sector is expected to benefit from margin recovery in 2026.
Congress trading data shows 4 recent sale transactions and no purchases, indicating a cautious stance. The company's Q4 financials show a decline in net income (-13.34% YoY), EPS (-9.55% YoY), and gross margin (-100% YoY). Additionally, Cantor Fitzgerald highlighted potential negative impacts from Medicare Advantage rate changes, which could weigh on the sector.
In Q4 2025, Cigna's revenue increased by 10.39% YoY to $72.47 billion. However, net income dropped by 13.34% YoY to $1.23 billion, and EPS fell by 9.55% YoY to 4.64. The gross margin dropped to 0, indicating significant cost pressures.
Analysts are broadly positive on Cigna, with several firms raising price targets (e.g., UBS to $375, Truist to $350, TD Cowen to $338). However, Barclays lowered its target slightly to $303, and Cantor Fitzgerald highlighted potential sector-wide challenges related to Medicare Advantage rates.
